KLP Kapitalforvaltning AS Grows Stock Holdings in Humana Inc. $HUM

KLP Kapitalforvaltning AS raised its position in shares of Humana Inc. (NYSE:HUM) by 5.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 46,070 shares of the insurance provider’s stock after purchasing an additional 2,400 shares during the period. KLP Kapitalforvaltning AS’s holdings in Humana were worth $11,835,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in HUM. CoreCap Advisors LLC increased its holdings in shares of Humana by 54.4% in the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after buying an additional 37 shares during the period. Rosenberg Matthew Hamilton increased its holdings in shares of Humana by 136.0% in the fourth quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock worth $30,000 after buying an additional 68 shares during the period. Mather Group LLC. purchased a new position in shares of Humana in the third quarter worth about $34,000. Private Wealth Management Group LLC increased its holdings in shares of Humana by 47.5% in the third quarter. Private Wealth Management Group LLC now owns 149 shares of the insurance provider’s stock worth $39,000 after buying an additional 48 shares during the period. Finally, Larson Financial Group LLC increased its holdings in shares of Humana by 114.1% in the third quarter. Larson Financial Group LLC now owns 152 shares of the insurance provider’s stock worth $40,000 after buying an additional 81 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Insider Buying and Selling at Humana

In other news, insider Sanjay K. Shetty bought 810 shares of Humana stock in a transaction on Monday, February 23rd. The shares were purchased at an average price of $185.21 per share, for a total transaction of $150,020.10. Following the acquisition, the insider owned 11,657 shares of the company’s stock, valued at approximately $2,158,992.97. The trade was a 7.47% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.20% of the company’s stock.

Humana Stock Down 1.2%

Shares of NYSE:HUM opened at $214.85 on Friday. Humana Inc. has a 1 year low of $163.11 and a 1 year high of $315.35. The company has a market cap of $25.79 billion, a PE ratio of 21.88, a P/E/G ratio of 2.33 and a beta of 0.44. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.00 and a quick ratio of 2.00. The stock’s 50-day moving average is $184.01 and its 200 day moving average is $229.67.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.01) by $0.05. Humana had a return on equity of 11.43% and a net margin of 0.92%.The company had revenue of $32.64 billion for the quarter, compared to the consensus estimate of $32.08 billion. During the same quarter in the previous year, the business earned ($2.16) EPS. Humana’s revenue was up 11.3% compared to the same quarter last year. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Sell-side analysts anticipate that Humana Inc. will post 9.05 EPS for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, June 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.6%. Humana’s dividend payout ratio is 36.05%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on HUM. TD Cowen decreased their price objective on Humana from $260.00 to $173.00 and set a “hold” rating on the stock in a report on Friday, February 13th. UBS Group reiterated a “neutral” rating on shares of Humana in a report on Wednesday, February 25th. Zacks Research downgraded Humana from a “hold” rating to a “strong sell” rating in a report on Tuesday, April 14th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Humana in a report on Tuesday. Finally, Barclays decreased their price objective on Humana from $245.00 to $176.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 24th. Seven investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat, Humana presently has an average rating of “Hold” and a consensus price target of $222.09.

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.